Marco Donia: Surgical considerations for TIL therapy in melanoma
Marco Donia, Research Group Leader of the TIL group at CCIT (Center for Cancer Immune Therapy) and Professor at the University of Copenhagen , shared a post on LinkedIn:
“Surgical considerations for TIL therapy in melanoma
In a collaboration between colleagues at The Netherlands Cancer Institute and our team at CCIT-DK – National Center for Cancer Immune Therapy of Denmark, we analysed every metastasectomy performed in the pivotal TIL vs ipilimumab phase III study
Key Points:
- 93 operations treated 80 patients with a 17 % rate of only mild (Clavien I/II) surgical complications.
- Lymph-node lesions had the lowest TIL outgrowth failure (≈3 %) compared with subcutaneous (≈19 %) and other sites (≈15 %).
- Lesion size (≤2 cm vs >4 cm) and number had no significant impact on manufacturing success or clinical response.
- Even incomplete resections were acceptable for successful TIL manufacture, helping minimise morbidity.
Clinical perspectives:
- Safe harvest from a broad range of metastatic sites: focus should be on accessibility & patient preference.
- A single, small lymph-node lesion is often enough; avoid extensive surgery when a low-impact option exists.
- Fast recovery (median 1 day in hospital) keeps patients on-track for subsequent lymphodepletion and TIL infusion.
Take home:
Minimal-morbidity surgery can reliably deliver potent TIL products.Congrats to the team Liselotte Tas, Marie Brinch-Møller Weitemeyer, Maartje Rohaan, Troels Holz Borch, Alexander van Akkooi, Inge Marie Svane, John Haanen, Lisbet Rosenkrantz Hölmich, Winan van Houdt and many others.”
Title: Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial
Authors: Liselotte Tas , Marie B Weitemeyer , Maartje W Rohaan , Troels H Borch , Alexander C J van Akkooi , Michel W J M Wouters , Koen J Hartemink , Yvonne M Schrage , Anke Kuijpers , Niels F M Kok , Maaike van Zon , Inge Jedema , Cynthia M Nijenhuis , Bastiaan Nuijen , Marten Hansen , Carlijn Voermans , Sebastian Klobuch , Tom T P Seijkens , Ferry Lalezari , Özcan Met , Marco Donia , I Marie Svane , John B A G Haanen , Lisbet R Hölmich , Winan J van Houdt
Read the Full Article.
Title: Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
Authors: Maartje W. Rohaan, Troels H. Borch, Joost H. van den Berg, Özcan Met, Rob Kessels, Marnix H. Geukes Foppen, Joachim Stoltenborg Granhøj, John B.A.G. Haanen
Read the Full Article.
More posts featuring Marco Donia.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023